Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom.

Autor:	La EM; Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC., Smyth EN; Oncology, Global Patient Outcomes and Real World Evidence, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN., Talbird SE; Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC., Li L; Real World Analytics, Oncology, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN., Kaye JA; Department of Epidemiology, RTI Health Solutions, Waltham, MA., Lin AB; Early Phase Medical, Oncology, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN., Bowman L; Oncology, Global Patient Outcomes and Real World Evidence, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN.
Jazyk:	angličtina
Zdroj:	European journal of cancer care [Eur J Cancer Care (Engl)] 2018 Sep; Vol. 27 (5), pp. e12862. Date of Electronic Publication: 2018 Jun 21.
DOI:	10.1111/ecc.12862
Abstrakt:	This study evaluated the patterns of care and health care resource use (HCRU) in patients with metastatic squamous cell carcinoma of the head and neck (SCCHN) who received ≥3 lines of systemic therapy in the United Kingdom (UK). Oncologists (n = 40) abstracted medical records for patients with metastatic SCCHN who initiated third-line systemic therapy during 1 January 2011-30 August 2014 (n = 220). Patient characteristics, treatment patterns and SCCHN-related HCRU were summarised descriptively for the metastatic period; exploratory multivariable regression analyses were conducted on select HCRU outcomes. At metastatic diagnosis, most patients had an Eastern Cooperative Oncology Group performance status (PS) of 0/1 (95%). For patients with PS 0/1, the most common first-line treatment was cisplatin+5-fluorouracil (5-FU); docetaxel was the most common second- and third-line treatment. For patients with PS ≥ 2, the most common first-, second-, and third-line treatments were carboplatin+5-FU, cetuximab, and methotrexate, respectively. Most patients received supportive care during (85%) and after (89%) therapy. This study provides useful information, prior to the availability of immunotherapy, on patient characteristics, treatment patterns, HCRU, and survival in a real-world UK population with metastatic SCCHN receiving ≥3 lines of systemic therapy. Patterns of care and HCRU varied among patients with metastatic SCCHN; specific systemic therapies varied by patient PS. (© 2018 Eli Lilly and Company. European Journal of Cancer Care published by John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu